Testing an AI-based test to avoid unnecessary prostate biopsies
Tests an AI-based prostate test to spare men with suspected prostate cancer a biopsy.
Key facts
- Who runs it
- Central Hospital, Nancy, France
- Where
- Vandœuvre-lès-Nancy, FranceSee the site
- Trial code
- Registry title
- Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy
- Status
- Not yet recruiting
- People taking part
- 150 people, planned
- Started
- 15 Apr 2025
- Planned end
- 1 Nov 2025
- Type of study
- Interventional
- Treatments tested
- PROSTia test
- Record updated
- 17 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men followed in the Urology Department at Nancy CHRU who can have a prostate biopsy to check for prostate cancer. It tests an artificial intelligence method that may help avoid some biopsies.
- Age
- Over 18 years
- Sex
- Men only
- Disease stage
- Suspected prostate cancer, with a biopsy planned because of a raised PSA, PSA density, or a lesion on MRI.
- Earlier treatment
- No earlier prostate biopsy.
Main reasons for not taking part
- Has already had a prostate biopsy
- Under court protection, guardianship or trusteeship
- Deprived of liberty by a judicial or administrative decision
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients followed up at the Nancy CHRU in the Urology Department and eligible for a prostate biopsy in search of prostate cancer, taking into account an increase in PSA, PSA density, lesion on MRI
- Person who has received full information about the organisation of the research and has not objected to their participation and the use of their data
- Adult male over 18 years of age - Patient affiliated to or benefiting from a social security scheme - Patient who understands French and is able to fill in a self-administered questionnaire or who has the possibility to be assisted in filling it in
Who cannot take part
- Patients who have already had a prostate biopsy
- Patients under court protection, guardianship or trusteeship
- Patients deprived of liberty by judicial or administrative decision
Where in France
- CHRU NancyVandœuvre-lès-Nancy, FranceContact: Pascal Principal investigator, MD PhDNo longer taking part
About the trial
What the trial wants to find out
The investigators are interested here in the contribution of a new prostate cancer screening method and, more specifically, in the new and somewhat futuristic approach of artificial intelligence in the development of new, more accurate algorithms that make it possible to rethink the benefits of mass generalisation of prostate biopsies.
Read full original descriptionShow less
Main objective The main objective of this research is to use artificial intelligence and an associated algorithm to identify new indicators that would make it possible to avoid a prostate biopsy in patients with an initial suspicion of prostate cancer.
The group in the trial
- Prostia testTreatment being tested
patients who responded to the PROSTia questionnaire
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy
- Plain-language title
- Testing an AI-based test to avoid unnecessary prostate biopsiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 April 2025